Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options.

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Abstract Text:

Michael K Herbert,Peter Holzer,

Inhibition of gastrointestinal motility is a major problem in critically ill patients. Motor stasis gives rise to subsequent complications including intolerance to enteral feeding, enhanced permeability of the atrophic intestinal mucosa and conditions as severe as systemic inflammatory response syndrome, sepsis and multiple organ failure. Although the diagnosis of motility disturbances in critically ill patients is difficult, the type and site of the disturbance are important to consider in the analysis of the condition and in the choice of therapeutic approach. The pharmacological treatment of impaired gastrointestinal motility is difficult to handle for the clinician, because the underlying mechanisms are complex and not fully understood and the availability of pharmacological treatment options is limited. In addition, there is a lack of controlled studies on which to build an evidence-based treatment concept for critically ill patients. Notwithstanding this situation, there has been remarkable progress in the understanding of the integrated regulation of gastrointestinal motility in health and disease. These advances, which largely relate to the organization of the enteric nervous system and its signaling mechanisms, enable the intensivist to develop a standardized concept for the use of prokinetic agents in the treatment of impaired gastrointestinal motility in critically ill patients.

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Publishing Authors By Initials

MK Herbert,P Holzer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical nutrition (Edinburgh, Scotland)

VOLUME: 27

Page Numbers: 25-41

Journal Abbreviation:

ISSN: 1532-1983

DAY: 22

MONTH: 10

YEAR: 2007

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309603

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options.

AFFILIATION: Department of Anaesthesiology, University of Wuerzburg, Oberduerrbacher Str. 6, 97080 Wuerzburg, Germany. Herbert_M@klinik.uni-wuerzburg.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Nutr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options Related Publications

• 227.
• Afferent signalling of gastric acid challenge.
• Deletion of the acid-sensing ion channel ASIC3 prevents gastritis-induced acid hyperresponsiveness of the stomach-brainstem axis.
• Experimental gastritis in mice enhances anxiety in a gender-related manner.
• First synthesis of 3-acetyl-2-aminothiophenes using the Gewald reaction.
• Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress.
• Olanzapine and blepharoclonus.
• Prevalence of major psychiatric illness in young adults who were burned as children.
• Proceedings: Characteristics and functions of proteinases and proteinase-inhibitors in yeast.
• Role of visceral afferent neurons in mucosal inflammation and defense.
• Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients--current status and future options.
• [DPN SYNTHESIS WITH NICOTINIC ACID AMIDE IN CELL FREE EXTRACTS OF EHRLICH ASCITES TUMOR CELLS.]
• [DPN content, nucleic acid content and cell structure of ascites tumor cells after administration of alkylating cytostatics.]
• [Edema and the tropics]
• [Four cases of pancreatic surgery; one case of generalized lithogenous pancreatitis.]
• [Is it a tropical disease? What should the practicing physician know?]
• [Malaria prophylaxis: what is safe?]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Protection against biting mosquitoes]
• [Reaction mechanism of thiamine pyrophosphate and thiamine]
• [Successful attempt to overcome the fear and insecurity in the presence of patients with AIDS. How I turned into a trusted companion]
• [The successful attempt to overcome anxiety and insecurity towards AIDS patients. How I turned into a reliable companion]
• [Tick borne diseases]